NCT05033522 2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3 Suspended
Clinical Trials
7 trialsNCT05250843 2023-10-13
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2/3 Unknown
NCT05001724 2023-04-25
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2/3 Terminated
NCT05322187 2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3 Unknown
NCT04319484 2020-03-24
LLTHVV
RenJi Hospital
Phase 2/3 Unknown
NCT04044651 2020-01-09
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
Sun Yat-sen University
Phase 2/3 Withdrawn
NCT04168944 2019-11-19
Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma
RenJi Hospital
Phase 2/3 Unknown